US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy

Patient reported outcomes for the CANDOR trial for multiple myeloma

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC